摘要
目的:比较卡泊芬净和伊曲康唑治疗侵袭性肺部真菌感染(IPFI)的有效性和安全性。方法:回顾性分析本院2010年9月–2011年8月入住呼吸科并诊断为IPFI的患者病例,记录患者一般情况、身体体征和临床表现的变化过程及不良反应,比较临床疗效和不良反应的发生情况,并进行统计分析。结果:卡泊芬净组36例,有效率为58.3%,伊曲康唑组31例,有效率为38.7%,两组有效率比较差异有统计学意义(P<0.05);卡泊芬净组和伊曲康唑组不良反应发生率分别为22.2%和54.8%;卡泊芬净组和伊曲康唑组因毒性反应停药的病例数分别为0例和4例,差异存在统计学意义(P<0.05)。结论:治疗侵袭性肺部真菌感染时,卡泊芬净比伊曲康唑具有更好的疗效且副作用小,需合理使用以减少耐药菌株的产生。
Objective： To compare the efficacy and safety of caspofungin and itraconazole in the treatment of invasive pulmonary fimgal infection （IPFI）. Methods： A retrospective analysis was applied to collect the data about the basic characteristics and signs of patients, clinical manifestation and adverse events in invasive pulmonary fungal infection patients in pneumology department from Sep 2010 to Aug 2011. And the clinical efficacy and the incidence of adverse reactions were compared and statistically analyzed between caspofungin and itraconazole group. Results： Caspofungin group had 36 cases and itraconazole group had 31 cases. The overall effective rates of caspofungin group and itraconazole group were 58.3% and 38.7%, with significant difference between two groups （P 〈 0.05）. The overall incidences of adverse reaction in caspofungin group and itraconazole group were 22.2% and 54.8%, respectively. There was significant difference in drug withdrawal after toxicity reaction between two groups （P 〈 0.05）, four patients changed to other medicines because of toxicity reaction in itraconazole group, while that did not occur in caspofungin group. Conclusion： Caspofungin was associated with better clinical outcomes （higher cure and fewer adverse effects） than itraconazole in the treatment of invasive pulmonary fungal infections, it should be used rationally in order to reduce the emergence of resistant strains.
出处
《中国药物应用与监测》
CAS
2012年第6期314-316,共3页
Chinese Journal of Drug Application and Monitoring
